Ibritumomab tiuxetan
Zevalin · Radioimmunotherapy (Y-90 anti-CD20)
Yttrium-90 radioimmunotherapy; tumor lysis with bulky lymphoma.
Jaypirca · Pirto
Non-covalent BTK inhibitor · approved 2023 · 6 citations · FAERS AKI reporting ROR 2.09 (95% CI 1.33–3.30, 19 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A non-covalent BTK inhibitor for CLL/MCL — clearing high tumor burden raises tumor-lysis risk.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Direct nephrotoxicity is not characteristic. Tumor lysis syndrome is an identified risk when rapidly debulking high-burden lymphoid malignancy; renal-specific incidence is low and not well quantified. BTK inhibitors as a class are also associated with hypertension and bleeding/atrial fibrillation (non-renal).Source: Mato et al., N Engl J Med 2023 (BRUIN)
Tumor lysis early after initiation in high-burden disease (first cycle), usually a single early event.
Distilled from: “Early after initiation in high-burden disease (first cycle); TLS is usually a single early event.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Tap a signature to trace where it strikes the nephron.
Crystal / Obstructive Nephropathy strikes: Tubular Lumen.
Crystal / Obstructive Nephropathy
Intratubular precipitation of drug or metabolite — high-dose methotrexate and tumor lysis crystals.
Reversible, non-covalent (non-C481-dependent) Bruton tyrosine-kinase inhibitor that retains activity against covalent-BTK-inhibitor-resistant disease, including C481S mutants. Approved for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle-cell lymphoma.
Class-level context for the major non-renal toxicities of the Non-covalent BTK inhibitor class.
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Quoted verbatim from this agent's current FDA label (Oct 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Severe renal impairment (eGFR 15-29 mL/min) increases pirtobrutinib exposure [see Clinical Pharmacology ( 12.3 )] . Reduce the JAYPIRCA dosage in patients with severe renal impairment [see Dosage and Administration ( 2.3 )] . No dosage adjustment of JAYPIRCA is recommended in patients with mild (60-89 mL/min) or moderate (30-59 mL/min) renal impairment.
Kidney rows of the label's dosage tables
From the JAYPIRCA label (Oct 2026) · DailyMed
No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 981 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
232 of 981 reports
Reported with hospitalization
284 of 981 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Pirtobrutinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Zevalin · Radioimmunotherapy (Y-90 anti-CD20)
Yttrium-90 radioimmunotherapy; tumor lysis with bulky lymphoma.
Leustatin · Purine analog
Tumor lysis; high-dose nephrotoxicity.
Etopophos · Topoisomerase II inhibitor
Tumor lysis; renally cleared.
Hydrea · Ribonucleotide reductase inhibitor
Tumor lysis in myeloproliferative disease.
Arranon · Purine analog
Tumor lysis in T-ALL.
Pomalyst · Immunomodulatory drug (IMiD)
Tumor lysis; usable in renal impairment.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.